155 related articles for article (PubMed ID: 31548345)
21. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.
Kim C; Tang G; Pogue-Geile KL; Costantino JP; Baehner FL; Baker J; Cronin MT; Watson D; Shak S; Bohn OL; Fumagalli D; Taniyama Y; Lee A; Reilly ML; Vogel VG; McCaskill-Stevens W; Ford LG; Geyer CE; Wickerham DL; Wolmark N; Paik S
J Clin Oncol; 2011 Nov; 29(31):4160-7. PubMed ID: 21947828
[TBL] [Abstract][Full Text] [Related]
22. Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing.
Yanagawa T; Kagara N; Miyake T; Tanei T; Naoi Y; Shimoda M; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2017 Jun; 163(2):231-240. PubMed ID: 28283903
[TBL] [Abstract][Full Text] [Related]
23. Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.
Clatot F; Perdrix A; Beaussire L; Lequesne J; Lévy C; Emile G; Bubenheim M; Lacaille S; Calbrix C; Augusto L; Guillemet C; Alexandru C; Fontanilles M; Sefrioui D; Burel L; Guénot S; Richard D; Sarafan-Vasseur N; Di Fiore F
Breast Cancer Res; 2020 May; 22(1):56. PubMed ID: 32466779
[TBL] [Abstract][Full Text] [Related]
24. Liver tropism of ER mutant breast cancer is characterized by unique molecular changes and immune infiltration.
Wu Y; Li Z; Lee AV; Oesterreich S; Luo B
Breast Cancer Res Treat; 2024 Jun; 205(2):371-386. PubMed ID: 38427312
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling.
Goto-Yamaguchi L; Yamamoto-Ibusuki M; Yamamoto Y; Fujiki Y; Tomiguchi M; Sueta A; Takeshita T; Iwase H
Breast Cancer Res Treat; 2018 Nov; 172(2):353-362. PubMed ID: 30151737
[TBL] [Abstract][Full Text] [Related]
26. Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer.
Sefrioui D; Perdrix A; Sarafan-Vasseur N; Dolfus C; Dujon A; Picquenot JM; Delacour J; Cornic M; Bohers E; Leheurteur M; Rigal O; Tennevet I; Thery JC; Alexandru C; Guillemet C; Moldovan C; Veyret C; Frebourg T; Di Fiore F; Clatot F
Int J Cancer; 2015 Nov; 137(10):2513-9. PubMed ID: 25994408
[TBL] [Abstract][Full Text] [Related]
27. Preexisting Somatic Mutations of Estrogen Receptor Alpha (
Dahlgren M; George AM; Brueffer C; Gladchuk S; Chen Y; Vallon-Christersson J; Hegardt C; Häkkinen J; Rydén L; Malmberg M; Larsson C; Gruvberger-Saal SK; Ehinger A; Loman N; Borg Å; Saal LH
JNCI Cancer Spectr; 2021 Apr; 5(2):. PubMed ID: 33937624
[TBL] [Abstract][Full Text] [Related]
28. Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.
Fribbens C; Garcia Murillas I; Beaney M; Hrebien S; O'Leary B; Kilburn L; Howarth K; Epstein M; Green E; Rosenfeld N; Ring A; Johnston S; Turner N
Ann Oncol; 2018 Jan; 29(1):145-153. PubMed ID: 29045530
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).
Pentheroudakis G; Kotoula V; Eleftheraki AG; Tsolaki E; Wirtz RM; Kalogeras KT; Batistatou A; Bobos M; Dimopoulos MA; Timotheadou E; Gogas H; Christodoulou C; Papadopoulou K; Efstratiou I; Scopa CD; Papaspyrou I; Vlachodimitropoulos D; Linardou H; Samantas E; Pectasides D; Pavlidis N; Fountzilas G
PLoS One; 2013; 8(7):e70634. PubMed ID: 23923010
[TBL] [Abstract][Full Text] [Related]
30. The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas.
Moreira-Dinzey J; Zhan H; Rozenblit M; Krishnamurti U; Harigopal M; Zhong M; Liang Y
Hum Pathol; 2023 Jul; 137():56-62. PubMed ID: 37127079
[TBL] [Abstract][Full Text] [Related]
31. High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer.
Endo Y; Toyama T; Takahashi S; Sugiura H; Yoshimoto N; Iwasa M; Kobayashi S; Fujii Y; Yamashita H
Int J Clin Oncol; 2011 Oct; 16(5):512-8. PubMed ID: 21431343
[TBL] [Abstract][Full Text] [Related]
32. Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients.
Tomita S; Zhang Z; Nakano M; Ibusuki M; Kawazoe T; Yamamoto Y; Iwase H
Cancer Sci; 2009 Jun; 100(6):1012-7. PubMed ID: 19320640
[TBL] [Abstract][Full Text] [Related]
33. Hypermethylation pattern of ESR and PgR genes and lacking estrogen and progesterone receptors in human breast cancer tumors: ER/PR subtypes.
Pirouzpanah S; Taleban FA; Mehdipour P; Sabour S; Atri M
Cancer Biomark; 2018 Feb; 21(3):621-638. PubMed ID: 29278880
[TBL] [Abstract][Full Text] [Related]
34. Molecular characterization of ESR1 variants in breast cancer.
Heeke AL; Elliott A; Feldman R; O'Connor HF; Pohlmann PR; Lynce F; Swain SM; Nunes MR; Magee D; Oberley MJ; Swenson J; Vidal G; Isaacs C; Schwartzberg L; Korn WM; Tan AR
Breast Cancer Res Treat; 2022 Nov; 196(2):279-289. PubMed ID: 36125660
[TBL] [Abstract][Full Text] [Related]
35. ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1.
Dunbier AK; Anderson H; Ghazoui Z; Lopez-Knowles E; Pancholi S; Ribas R; Drury S; Sidhu K; Leary A; Martin LA; Dowsett M
PLoS Genet; 2011 Apr; 7(4):e1001382. PubMed ID: 21552322
[TBL] [Abstract][Full Text] [Related]
36. ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients.
Martínez-Galán J; Torres-Torres B; Núñez MI; López-Peñalver J; Del Moral R; Ruiz De Almodóvar JM; Menjón S; Concha A; Chamorro C; Ríos S; Delgado JR
BMC Cancer; 2014 Feb; 14():59. PubMed ID: 24495356
[TBL] [Abstract][Full Text] [Related]
37. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
38. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.
Chandarlapaty S; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Voi M; Gnant M; Hortobagyi G; Baselga J; Moynahan ME
JAMA Oncol; 2016 Oct; 2(10):1310-1315. PubMed ID: 27532364
[TBL] [Abstract][Full Text] [Related]
39. Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital.
Bardia A; Iafrate JA; Sundaresan T; Younger J; Nardi V
Oncologist; 2016 Sep; 21(9):1035-40. PubMed ID: 27551012
[TBL] [Abstract][Full Text] [Related]
40. Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.
López-Knowles E; Wilkerson PM; Ribas R; Anderson H; Mackay A; Ghazoui Z; Rani A; Osin P; Nerurkar A; Renshaw L; Larionov A; Miller WR; Dixon JM; Reis-Filho JS; Dunbier AK; Martin LA; Dowsett M
Breast Cancer Res; 2015 Mar; 17(1):35. PubMed ID: 25888249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
